GSK and Ionis achieve Phase 3 success for hepatitis B treatment

On January 7, 2026, GSK and Ionis Pharmaceuticals announced a significant milestone in the treatment of chronic hepatitis B with their experimental drug, bepirovirsen. The drug successfully met its primary endpoints in two Phase 3 clinical trials, demonstrating statistically significant functional cure rates for patients. This achievement opens the door for global regulatory filings, with plans to submit data in the first quarter of 2026, potentially marking a new era in hepatitis B treatment.

The Phase 3 trials, known as the B-Well 1 and B-Well 2 studies, have shown promising results, although specific details regarding the outcomes have not yet been disclosed. Bepirovirsen is designed to provide a functional cure for chronic hepatitis B infections, which affect a substantial number of individuals worldwide. Estimates indicate that over 2 billion people have been infected with the hepatitis B virus, and nearly 300 million have chronic infections. The potential impact of bepirovirsen could be profound.

Currently, many patients with chronic hepatitis B require lifelong antiviral treatments to manage their condition. However, bepirovirsen is being developed as a six-month treatment course that could reduce the virus to undetectable levels. This could allow patients to discontinue long-term medication while still preventing the adverse effects associated with the virus, such as cirrhosis and liver cancer. The market for effective hepatitis B therapies is significant, with existing treatments like Gilead’s Vemlidy generating substantial revenue.

The success of bepirovirsen could meet a critical demand for more effective and manageable treatment options for patients. The importance of vaccination in preventing hepatitis B infections is also highlighted, as government vaccination programs have significantly reduced cases in infants and children in the U.S. Ionis developed bepirovirsen and licensed it to GSK in 2019, and the partnership could yield substantial financial incentives based on regulatory and sales milestones.

As the companies prepare for regulatory submissions, the full trial results are expected to be presented at future medical meetings and published in peer-reviewed journals. The advancement of bepirovirsen represents a hopeful step towards providing a functional cure for chronic hepatitis B, potentially transforming the treatment landscape for millions of patients worldwide.